Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma

dc.authorid Köseoğlu, Hikmet/0000-0001-5678-4981
dc.authorwosid Köseoğlu, Hikmet/A-8081-2008
dc.contributor.author Koseoglu, Hikmet
dc.contributor.author Cenkeri, Halime Cevik
dc.contributor.author Eroglu, Tolga
dc.contributor.author Yalcin, Berrin
dc.date.accessioned 2024-05-25T11:37:58Z
dc.date.available 2024-05-25T11:37:58Z
dc.date.issued 2023
dc.department Okan University en_US
dc.department-temp [Koseoglu, Hikmet] Hlth Sci Univ, Hamidiye Fac Med, Istanbul Hlth Practice & Res Ctr, Dept Urol, Istanbul, Turkiye; [Cenkeri, Halime Cevik] Okan Univ, Fac Med, Dept Radiol, Istanbul, Turkiye; [Eroglu, Tolga] Semdinli State Hosp, Dept Urol, Hakkari, Turkiye; [Yalcin, Berrin] Hlth Sci Univ, Hamidiye Fac Med, Istanbul Hlth Practice & Res Ctr, Dept Radiat Oncol, Istanbul, Turkiye en_US
dc.description Köseoğlu, Hikmet/0000-0001-5678-4981 en_US
dc.description.abstract Purpose: Implementation of multiparametric magnetic resonance imaging (mpMRI) for prostate adenocarcino-ma's variant pathology requires awareness. The aim of this retrospective study was to investigate the discriminant efficacy of multiparametric magnetic resonance imaging modality for variant pathology associated with prostate adenocarcinoma. Methods: Consecutive 247 prostate cancer patients who underwent radical prostatectomy in our university-based hospital between October 2014 and October 2019, were retrospectively reviewed. Data of mpMRI-associated contrast enhancements, T2 signals, apparent diffusion coefficients (ADC), ages, and PSA values were compared. Clinical and demographic data of patients were noted including associated variant pathologies and reports of pre-operative mpMRI images. Results: Among the patients, 63 (26%) had variant pathology and 14 (22%) had mpMRI before primary prostate biopsy. The group with variant pathology and the control group had similar perfusion curves and increased contrast when compared for mpMRI parameters, but different ADC values for each of the adjusted b-values for 400, 800 and 1400. Conclusion: Our study demonstrates that mpMRI appears to have no role in distinguishing rare variant pathologies associated with prostate adenocarcinoma despite different ADC values. en_US
dc.description.sponsorship [10-11 Oc- tober 2020] en_US
dc.description.sponsorship ACKNOWLEDGEMENT It was presented as poster in the 40th Congress of the Societe Internationale d'Urologie- Virtual, 10-11 Oc- tober 2020. en_US
dc.identifier.citationcount 0
dc.identifier.doi 10.22037/uj.v20i.7468]
dc.identifier.endpage 161 en_US
dc.identifier.issn 1735-1308
dc.identifier.issn 1735-546X
dc.identifier.issue 3 en_US
dc.identifier.pmid 36840448
dc.identifier.startpage 157 en_US
dc.identifier.uri https://doi.org/10.22037/uj.v20i.7468]
dc.identifier.uri https://hdl.handle.net/20.500.14517/1235
dc.identifier.volume 20 en_US
dc.identifier.wos WOS:000996100500004
dc.language.iso en
dc.publisher Urol & Nephrol Res Ctr-unrc en_US
dc.relation.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
dc.rights info:eu-repo/semantics/closedAccess en_US
dc.subject prostate adenocarcinoma en_US
dc.subject prostate cancer variants en_US
dc.subject mpMRI en_US
dc.subject apparent diffusion coefficient en_US
dc.title Discriminant Efficacy of mpMRI for Variant Pathology Associated with Prostate Adenocarcinoma en_US
dc.type Article en_US
dc.wos.citedbyCount 0

Files